company background image
DSGN

Design Therapeutics NasdaqGS:DSGN Stock Report

Last Price

US$8.27

Market Cap

US$461.8m

7D

-7.3%

1Y

-33.9%

Updated

28 Jan, 2023

Data

Company Financials +

Design Therapeutics, Inc.

NasdaqGS:DSGN Stock Report

Mkt Cap: US$461.8m

DSGN Stock Overview

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions.

DSGN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Design Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Design Therapeutics
Historical stock prices
Current Share PriceUS$8.27
52 Week HighUS$26.30
52 Week LowUS$6.94
Beta0
1 Month Change-19.71%
3 Month Change-48.63%
1 Year Change-33.89%
3 Year Changen/a
5 Year Changen/a
Change since IPO-80.07%

Recent News & Updates

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Oct 25
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Recent updates

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Oct 25
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

Jul 02
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Mar 18
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Dec 03
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Aug 18
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Shareholder Returns

DSGNUS BiotechsUS Market
7D-7.3%0.8%2.8%
1Y-33.9%7.1%-9.2%

Return vs Industry: DSGN underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: DSGN underperformed the US Market which returned -9.7% over the past year.

Price Volatility

Is DSGN's price volatile compared to industry and market?
DSGN volatility
DSGN Average Weekly Movement14.2%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: DSGN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: DSGN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201756João Sifferthttps://www.designtx.com

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company’s portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy.

Design Therapeutics, Inc. Fundamentals Summary

How do Design Therapeutics's earnings and revenue compare to its market cap?
DSGN fundamental statistics
Market CapUS$461.80m
Earnings (TTM)-US$57.03m
Revenue (TTM)n/a

0.0x

P/S Ratio

-8.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DSGN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$27.07m
Gross Profit-US$27.07m
Other ExpensesUS$29.96m
Earnings-US$57.03m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.02
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did DSGN perform over the long term?

See historical performance and comparison